Aptol Pharma ApS: Financial statements 2022
CVR: 39308967
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Aptol Pharma ApS (CVR 39308967) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -421,544 and a net result of DKK -334,362 compared with DKK 0 the year before. Equity in the 2022 report amounted to DKK -317,026.
- Gross Profit
- DKK -421,544
- Profit/Loss
- DKK -334,362
- Equity
- DKK -317,026
- Total Assets
- DKK 103,645
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -422 t. | -334 t. | -317 t. | - |
| 2021 | 0 | 0 | 0 | 50 t. | - |
| 2020 | 0 | -137 t. | -2 t. | 50 t. | - |
| 2019 | 0 | -102 t. | -2 t. | 50 t. | - |
| 2018 | 0 | 89 t. | 129 t. | 50 t. | - |
Keep an eye on Aptol Pharma ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
On May 25, 2022, the company changed its name from IBIO TECH ApS to Aptol Pharma ApS.
Aptol Pharma ApS has published its annual report for 2021. Revenue came to DKK 0, and the net result was DKK 0.
About Aptol Pharma ApS
Aptol Pharma ApS is a Danish company of the type Anpartsselskab based in København SV, founded in 2018. The company is under bankruptcy. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named IBIO TECH ApS and Integrated biomedical technologies ApS. The company's owners include ADT HOLDING ApS, Tue Wenzel Kragstrup and Peter Andreas Nicolai Reumert Wagtmann. According to the 2024 annual report, the company had an average of 1 employee. In 2024, the company reported a gross profit of DKK 2,442 and a net result of DKK -131,289 compared with DKK 307,979 the year before. Equity in the 2024 report amounted to DKK -140,336.